Jazz Pharmaceuticals Non-GAAP EPS of -$3.88 misses by $1.50, revenue of $1.24B beats by $30M (JAZZ:NASDAQ)
· seekingalpha.com
Jazz Pharmaceuticals Q3 results: EPS missed, revenue beat, and 2026 revenue guidance was raised.
To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
If you have an ad-blocker enabled you may be blocked from ...